MX2011006335A - Formulacion de deposito de octreotida con niveles de exposicion constantemente altos. - Google Patents

Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.

Info

Publication number
MX2011006335A
MX2011006335A MX2011006335A MX2011006335A MX2011006335A MX 2011006335 A MX2011006335 A MX 2011006335A MX 2011006335 A MX2011006335 A MX 2011006335A MX 2011006335 A MX2011006335 A MX 2011006335A MX 2011006335 A MX2011006335 A MX 2011006335A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
composition according
microparticles
octreotide
plgas
Prior art date
Application number
MX2011006335A
Other languages
English (en)
Spanish (es)
Inventor
Holger Petersen
Markus Ahlheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40520410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011006335(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2011006335A publication Critical patent/MX2011006335A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/19Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/24Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2011006335A 2008-12-15 2009-12-14 Formulacion de deposito de octreotida con niveles de exposicion constantemente altos. MX2011006335A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08171712 2008-12-15
PCT/EP2009/067049 WO2010079047A2 (en) 2008-12-15 2009-12-14 Octreotide depot formulation with constantly high exposure levels

Publications (1)

Publication Number Publication Date
MX2011006335A true MX2011006335A (es) 2011-07-13

Family

ID=40520410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006335A MX2011006335A (es) 2008-12-15 2009-12-14 Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.

Country Status (25)

Country Link
US (10) US20100151033A1 (cg-RX-API-DMAC7.html)
EP (1) EP2376070B1 (cg-RX-API-DMAC7.html)
JP (1) JP5721635B2 (cg-RX-API-DMAC7.html)
KR (1) KR101708517B1 (cg-RX-API-DMAC7.html)
CN (3) CN105233251A (cg-RX-API-DMAC7.html)
AR (1) AR074603A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009336718B9 (cg-RX-API-DMAC7.html)
BR (1) BRPI0922607B1 (cg-RX-API-DMAC7.html)
CA (1) CA2746968C (cg-RX-API-DMAC7.html)
CL (1) CL2011001438A1 (cg-RX-API-DMAC7.html)
CO (1) CO6382109A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011199A (cg-RX-API-DMAC7.html)
ES (1) ES2602614T3 (cg-RX-API-DMAC7.html)
IL (1) IL213034A (cg-RX-API-DMAC7.html)
MA (1) MA32964B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011006335A (cg-RX-API-DMAC7.html)
MY (1) MY159789A (cg-RX-API-DMAC7.html)
NZ (1) NZ592998A (cg-RX-API-DMAC7.html)
PE (1) PE20110876A1 (cg-RX-API-DMAC7.html)
PL (1) PL2376070T3 (cg-RX-API-DMAC7.html)
PT (1) PT2376070T (cg-RX-API-DMAC7.html)
RU (1) RU2526822C2 (cg-RX-API-DMAC7.html)
SG (1) SG171255A1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000261A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010079047A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
RU2695522C2 (ru) * 2012-05-14 2019-07-23 Тейдзин Лимитед Стерильная композиция
PT3125871T (pt) * 2014-03-31 2021-01-06 Pharmathen Sa Preparação de microsferas de plga carregadas com péptido com características de libertação controlada
IL285440B1 (en) 2014-12-10 2025-09-01 Amryt Endo Inc Oral preparations containing octreotide in combination with other medicinal substances for the treatment of acromegaly
EP4527456A3 (en) 2015-02-03 2025-05-21 Amryt Endo, Inc. Treating acromegaly with oral octreotide
CN105963258B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
KR20250004925A (ko) 2017-09-15 2025-01-08 옥슬러 리미티드 안과용 약물 조성물
JP7704740B2 (ja) 2019-09-16 2025-07-08 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌の方法
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
GB9513224D0 (en) * 1995-06-29 1995-09-06 Sandoz Ltd Organic compounds
KR20050088288A (ko) * 2002-11-06 2005-09-05 알자 코포레이션 제어식 방출 데포 제형
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
JP2008524235A (ja) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー,インコーポレイテッド. オクトレオチド化合物の徐放性送達処方物
ES2492641T3 (es) * 2005-12-22 2014-09-10 Novartis Ag Formulación de liberación sostenida que comprende octreótida y dos o más polímeros de poliláctida-co-glicólido

Also Published As

Publication number Publication date
US20100151033A1 (en) 2010-06-17
BRPI0922607A2 (pt) 2015-12-22
TN2011000261A1 (en) 2012-12-17
US20240082148A1 (en) 2024-03-14
PE20110876A1 (es) 2011-12-21
MA32964B1 (fr) 2012-01-02
RU2011128538A (ru) 2013-01-20
EP2376070A2 (en) 2011-10-19
US20160089336A1 (en) 2016-03-31
BRPI0922607B1 (pt) 2019-11-05
PL2376070T3 (pl) 2017-04-28
SG171255A1 (en) 2011-07-28
JP2012512147A (ja) 2012-05-31
AU2009336718B2 (en) 2014-01-30
IL213034A0 (en) 2011-07-31
US20210161806A1 (en) 2021-06-03
US20250205147A1 (en) 2025-06-26
WO2010079047A2 (en) 2010-07-15
CN102245210A (zh) 2011-11-16
AU2009336718A1 (en) 2011-06-30
US20110262545A1 (en) 2011-10-27
CO6382109A2 (es) 2012-02-15
CL2011001438A1 (es) 2011-11-04
WO2010079047A3 (en) 2010-09-16
KR101708517B1 (ko) 2017-02-20
US20170143791A1 (en) 2017-05-25
CA2746968A1 (en) 2010-07-15
CN105031607A (zh) 2015-11-11
HK1159505A1 (zh) 2012-08-03
ECSP11011199A (es) 2011-08-31
MY159789A (en) 2017-01-31
PT2376070T (pt) 2016-11-16
US20140363513A1 (en) 2014-12-11
US20180036230A1 (en) 2018-02-08
ES2602614T3 (es) 2017-02-21
US20190209462A1 (en) 2019-07-11
AR074603A1 (es) 2011-01-26
RU2526822C2 (ru) 2014-08-27
NZ592998A (en) 2013-02-22
KR20110104042A (ko) 2011-09-21
IL213034A (en) 2017-04-30
AU2009336718B9 (en) 2014-04-03
EP2376070B1 (en) 2016-08-10
CA2746968C (en) 2016-10-04
JP5721635B2 (ja) 2015-05-20
CN105233251A (zh) 2016-01-13

Similar Documents

Publication Publication Date Title
US20250205147A1 (en) Octreotide Depot Formulation with Constantly High Exposure Levels
US20200206306A1 (en) Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
US8999390B2 (en) Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
US20100266704A1 (en) Octreotide depot formulation with constantly high exposure levels
AU2013201877B2 (en) Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
HK1159505B (en) Octreotide depot formulation with constantly high release rates

Legal Events

Date Code Title Description
FG Grant or registration